A novel drug to treat gum diseases.

Evaluation of clinical and antimicrobial efficacy of chitosan nanoparticle gel (1%) as a local drug delivery in chronic periodontitis patients- a randomised controlled split mouth trial.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/05/019477

Enrollment

Registered

2019-05-31

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B998- Other infectious disease

Interventions

Intervention1: Local drug delivery: Local drug delivery to eliminate periodontopathogens compared with scaling and root planing alone. Intervention2: local drug delivery: Comparison of results obtaine

Eligibility

Inclusion criteria

Inclusion criteria: Probing pocket depth 5mm to 8mm. Clinical attachment level of 3mm. Vertical bone loss greater than 3mm on digital radiographs

Exclusion criteria

Exclusion criteria: Patients with systemic diseases. Patients who have undergone periodontal treatment in last 6 months. Pregnant and lactating mothers. Smokers, alcoholics, drug abusers.

Design outcomes

Primary

Measure	Time frame
To evaluate the antimicrobial efficacy of Chitosan nanoparticle gel (1%) as local drug delivery against periopathogens Porphyromonas gingivalis, Tanerella forsythia.Timepoint: 6 weeks interval	—

Secondary

Measure	Time frame
Gingival index,plaque index,Timepoint: 6 week interval	—

Countries

India

Contacts

Public ContactNageswaran GR

Dayananda Sagar College of Dental Sciences

amsavita25@yahoo.com9845433660

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026